Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13689264 | 0.90 | SMN1; SMN2 (0.48) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| SCHEMBL2625199 | 0.81 | PKM (0.54) | CYP2C19RAB9APOLBSMN1; SMN2NPC1 | |
| Isobutyramide SCHEMBL28394293 | 0.80 | POLB (0.53) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| SCHEMBL4232556 | 0.79 | POLB (0.50) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| SCHEMBL7332254 | 0.79 | TAAR1 (0.54) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| Cyclohexane SCHEMBL27561998 | 0.77 | PKM (0.50) | CYP2C19RAB9APOLBSMN1; SMN2NPC1 | |
| Cyclopentane SCHEMBL27504248 | 0.77 | PKM (0.50) | CYP2C19RAB9APOLBSMN1; SMN2NPC1 | |
| SCHEMBL6197785 | 0.77 | TAAR1 (0.52) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| SCHEMBL654985 | 0.77 | POLB (0.66) | CYP2C19RAB9APOLBTDP1TAAR1 | |
| SCHEMBL25097666 | 0.77 | CYP2C19 (0.41) | CYP2C19RAB9APOLBTDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20050075390-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6852711-B2 | Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040106606-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2004-06-03 | — | — | US | disclosed |
| US-6528510-B1 | Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| EP-1112269-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015634-A2 | HIV PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | CYP2C19 899/4885RAB9A 4102/4885POLB 4020/4885 |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CYP2C19 681/4885RAB9A 977/4885POLB 2532/4885 |
| US-20090281322-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS | GOT1, GOT2, NDUFA7 | CYP2C19 1528/4885RAB9A 1966/4885POLB 3342/4885 |
| US-20040106606-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | CYP2C19 932/4885RAB9A 3077/4885POLB 1862/4885 |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CYP2C19 681/4885RAB9A 977/4885POLB 2532/4885 |
| US-20050075390-A1 | HIV protease inhibitors | DNPEP, PREP, PEPD | CYP2C19 1034/4885RAB9A 3024/4885POLB 1760/4885 |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | CYP2C19 681/4885RAB9A 977/4885POLB 2532/4885 |
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | CYP2C19 4716/4885RAB9A 1024/4885POLB 2140/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | CYP2C19 926/4885RAB9A 4701/4885POLB 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.